Neurotech International (ASX:NTI)
ASX announcement history & article coverage
Transparent by design.
Announcments by Neurotech International (ASX:NTI) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Ceasing to be a substantial holder
Corporate Presentation
Becoming a substantial holder
Change of Director's Interest Notice
Annual Report (Typeset)
Neurotech advances NTI164 into Phase III while annual report flags going concern uncertainty
Notice of Annual General Meeting/Proxy Form
NTI Doses First Patient in Phase 3 Beyond Harmony ASD Study
Neurotech doses first patient in pivotal Phase 3 autism study
Initial Director's Interest Notice
Notification of cessation of securities - NTI
Board and Management Changes
Final Director's Interest Notice
Appendix 4G and Corporate Governance Statement
Appendix 4E & Annual Report to shareholders
Neurotech advances Phase 3 ASD trial, cuts loss 38%, raises $3.75M
Appointment of Executive Chairman
Becoming a substantial holder
Secondary Trading Notice
Application for quotation of securities - NTI
Proposed issue of securities - NTI
Proposed issue of securities - NTI
Receipt of Binding Commitments for $4.5m Placement
Neurotech raises $4.5 million placement to fund Phase III ASD trial
Quarterly Activities/Appendix 4C Cash Flow Report
Neurotech advances NTI164 with FDA IND clearance, patent progress, and expanded prescriber program
Trading Halt
NTI164 Phase II/III Autism Data Accepted for Publication